ENTPD1 and rheumatoid arthritis: As a result, detecting low CD39 mean fluorescence intensity (MFI) on Tregs using FACS on a small sample of whole peripheral blood represents a noninvasive, rapid, and convenient procedure for predicting MTX nonresponsiveness in RA patients with >99 percent confidence, and thus represents a valuable option for RA therapy (16).